Eli Lilly's goal is to reach everyone who needs obesity care: Global CEO David Ricks

Eli Lilly's CEO David Ricks discusses the launch of diabetes and anti-obesity drugs Mounjaro and Zepbound, focusing on expanding access in emerging markets. He highlights new weight-loss drugs and emphasizes the importance of partnerships, including with Indian tech companies and governments, for tackling chronic diseases and improving public health in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eNdVU6C
via IFTTT